Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sodimu, Adetoun, Bartolome, Sonja, Igenoza, Oluwatosin P., Chin, Kelly M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691907/
https://www.ncbi.nlm.nih.gov/pubmed/33282204
http://dx.doi.org/10.1177/2045894020971954
_version_ 1783614394409680896
author Sodimu, Adetoun
Bartolome, Sonja
Igenoza, Oluwatosin P.
Chin, Kelly M.
author_facet Sodimu, Adetoun
Bartolome, Sonja
Igenoza, Oluwatosin P.
Chin, Kelly M.
author_sort Sodimu, Adetoun
collection PubMed
description In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.
format Online
Article
Text
id pubmed-7691907
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76919072020-12-04 Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study Sodimu, Adetoun Bartolome, Sonja Igenoza, Oluwatosin P. Chin, Kelly M. Pulm Circ Research Letter In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints. SAGE Publications 2020-11-25 /pmc/articles/PMC7691907/ /pubmed/33282204 http://dx.doi.org/10.1177/2045894020971954 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Letter
Sodimu, Adetoun
Bartolome, Sonja
Igenoza, Oluwatosin P.
Chin, Kelly M.
Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title_full Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title_fullStr Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title_full_unstemmed Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title_short Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
title_sort hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691907/
https://www.ncbi.nlm.nih.gov/pubmed/33282204
http://dx.doi.org/10.1177/2045894020971954
work_keys_str_mv AT sodimuadetoun hemodynamiceffectsoffluoxetineinpulmonaryarterialhypertensionanopenlabelpilotstudy
AT bartolomesonja hemodynamiceffectsoffluoxetineinpulmonaryarterialhypertensionanopenlabelpilotstudy
AT igenozaoluwatosinp hemodynamiceffectsoffluoxetineinpulmonaryarterialhypertensionanopenlabelpilotstudy
AT chinkellym hemodynamiceffectsoffluoxetineinpulmonaryarterialhypertensionanopenlabelpilotstudy

Ejemplares similares